The use of retroviral vectors in research laboratories has been steadily increasing, and with that, questions are arising more frequently regarding the biosafety of these reagents, particularly when the vector delivers a gene with oncogenic properties. Although modern retroviral vector systems produce particles that are replication-defective, there is still a possibility that upon accidental exposure, cells within a laboratory worker could be permanently modified and that this may increase the risk of malignant transformation. This brief review summarizes some published research that bears relevance to this risk and is intended to help investigators, IBC staff, and occupational health professionals establish policies to minimize the risk of working with these reagents. Questions regarding the actions that should be taken to prevent and respond to accidental exposure are presented and discussed.
Introduction
Retroviral vectors can permanently alter cellular genomic DNA by inserting a gene expression cassette into the chromosome and, as such, are valuable tools for studying the effect of genes on the growth and differentiation of cells. This tool is often implemented in cancer research by modifying cells ex vivo to express candidate oncogenes, followed by reintroduction of the modified cells into animals and scoring subsequent tumor development. In this context, the risk of accidental exposure with an oncogenic vector to laboratory personnel should be considered with regard to the potential that the vector could transduce tissue in vivo and facilitate a transformation event, leading to an increased risk of cancer over the life of the exposed individual. This risk occurs in spite of the fact that the most common retroviral vectors are replication defective, and they cannot undergo more than a single round of transduction. They are, therefore, not truly infectious agents, as they cannot establish a productive infection in an individual that is capable of spreading into the general population. The risk of tumorigenesis with the use of oncogene-containing vectors should, therefore, be evaluated as potentially carcinogenic substances rather than hazardous infectious agents. It is possible for some retroviral vector production systems to sporadically generate replicationcompetent retrovirus contaminants, which could potentially create a spreading, tumorigenic virus infection, but modern vector production systems have reduced these contaminants to undetectable levels. As most investigators use these safer production systems, this discussion is specifically limited to the risk associated with fully replication-defective vectors. For a review of general retrovirus vector safety, not focused on oncogenecontaining vectors, see Mosier (2004) .
This review addresses the safety of oncogenecontaining vectors by first explaining the relevant basic retrovirus biology, and then trying to provide examples of published data that will help evaluate the likelihood that an accidental exposure to a laboratory worker would: 1) cause significant levels of transduction; and 2) at some level of transduction would increase the risk of cancer. These risks are then discussed in the context of developing institutional policies for managing work with these types of reagents.
Retrovirus Vector Basics
To evaluate the potential risk of accidental transformative events, it is necessary to understand some basic concepts of retroviral vectorology. For further reading on retroviruses and their use as vectors, please refer to Retrovirology (Coffin, 199 7) , available free online via the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov). Retroviral vectors are produced in immortalized cell lines engineered to express: 1) the necessary protein-coding genes to generate viral particles; and 2) a vector RNA genome that is packaged into the viral particle. These "producer cells" secrete vector particles into the medium and are typically processed by filtration or optionally by column purification or ultracentrifugation techniques. Retroviral vector concentration is typically determined by an infectious titration assay on a standard immortalized cell line, such as Hela or HEK-293, by determining the number or fraction of cells that have the vector genome integrated (a "transduction" event) after treatment with a given volume of a vector preparation. Typical titers for unprocessed supernatants are between 10 6 -10 8 transducing units (TU)/ ml, and those of concentrated preparations can extend up to 10 10 TU/ ml. The level of gene delivery achieved by a vector preparation (both with regard to the number of cells transduced and the number of transductions per cell) is critically dependent upon the concentration of vector during the incubation of the vector with cells.
Retroviral vectors can be produced with any one of a number of different envelopes, (referred to as vector "pseudotypes"), which each confer distinct cellular tro-
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Laboratory Safety for Oncogene-Containing Retroviral Vectors John T. Gray* St. Jude Children's Research Hospital, Memphis, Tennessee pism. "Ecotropic" envelope vectors can transduce only mouse (and not human) cells, providing enhanced safety for laboratory personnel. The most commonly used pseudotype is the Vesicular Stomatitis Virus glycoprotein G (VSV-G), because it provides high human cell transduction, broad tissue tropism, and excellent particle stability during post-production processing steps, such as ultracentrifugation. After binding to the surface of a cell, retroviral vector particles are internalized, whereupon the genomic RNA is reverse-transcribed to generate a double-stranded DNA molecule competent for integration. The "pre-integration complex" containing this DNA must then gain access to cellular genomic DNA, which in dividing cells can occur as the nuclear envelope breaks down during cell division. Lentiviral vectors, such as those derived from Human Immunodeficiency Virus (HIV), are capable of transducing non-dividing cells by utilizing an active transport process to migrate through the nuclear pore to access the nucleus, providing a distinct advantage of this vector system over traditional gammaretroviral vectors based on Murine Leukemia Virus (MLV). The final step of the transduction process occurs when the viral integrase enzyme mediates integration of the proviral DNA into the genome. The efficiency of the entire infection process can vary dramatically among different cells. In general, immortalized cells grown in vitro are more easily transduced than primary cells, and resting primary cells are more difficult to transduce than dividing primary cells. Even for lentiviruses, transducing primary cell types can require over 10-fold higher vector titer than is necessary for transducing HEK293 or HeLa cells.
The Risk that Accidental Exposure Will Cause Significant Transduction
The transmission of HIV in people and MLV in mice has been studied and shown to typically occur by direct contact with infected fluids such as saliva, semen, or blood. For HIV, there is no evidence of transmission by casual contact or the bites of mosquitoes (Coffin, 1997) . However, the Vesicular Stomatitis Virus and other Rhabdoviruses can be transmitted by aerosol inoculation of airway epithelium (Knipe, 2007) , and so it is possible that this transmission property could be conferred to VSV-G pseudotyped lentiviral particles. VSV-G pseudotyped lentiviral vectors have been used to transduce murine airway epithelium for gene therapy applications (Stocker et al., 2009 ), although in that example transduction was observed only when lungs were pre-treated with a natural surfactant. Efficient transduction of human skin epidermis and dermis by both VSV-G and amphotropic MLV pseudotyped lentiviral particles has been observed (Kunicher et al., 2008) , in this case by incubating tissue explants in liquid medium containing 10 8 TU/ ml of vector. Transduction of human skin cells was more efficient than that of murine origin. It is not clear wheth-er intact skin would be transduced with similar efficiencies. With regard to accidental exposure to the eye, direct injection of VSV-G pseudotyped lentiviral vectors into porcine corneal pockets created by laser resection techniques did result in significant transduction of corneal stromal cells (Bemelmans et al., 2009 ), but again it is not clear whether in the absence of the laser resection significant transduction would occur. In that publication the authors do comment (without providing data) that bathing human corneas without laser resection does cause surface cell transduction without transduction of cells beneath the surface.
In the event of an accidental needlestick with lentiviral vectors, it appears more likely that significant transduction would occur. Pan et al. (2002) performed a careful in vivo biodistribution and toxicity study after intravenous administration of a VSV-G pseudotyped lentiviral vector into mice. In this experiment approximately 10 7 HEK293 transducing units (equivalent to 10 µl of hightiter concentrated vector preparation) were injected via tail vein into 17 normal BALB / c mice. No pathological findings outside of normal were observed for this GFP encoding vector when these animals were sacrificed at 4 and 40 days. Quantitation of vector biodistribution at 4 days post-infusion, as determined by quantitative PCR, showed significant vector genomes in liver (12-59 vector copies per 100 cell genome equivalents, reported hereafter as percent), bone marrow (5%-37%), and spleen (20%-54%). After 40 days, marking had decreased in liver (0.3%-1%) and spleen (0.045%-0.38%) but remained high in the bone marrow (4.7%-22.7%). Flow cytometry analysis for (green fluorescent protein) GFP fluorescence also indicated significant peripheral blood leukocyte transduction at this 40-day time point (average 20.8%), but lower marking at earlier time points (e.g., 0.73% at day 25), suggesting that progenitor transduction in the marrow led to later marking in differentiated lineages.
One might expect that the blood complement system would significantly reduce the level of gene transfer for vectors gaining access to peripheral circulation, although the magnitude of this effect is difficult to predict. VSV-G pseudotyped retroviral vectors in particular have been shown to be inactivated by human blood complement when incubated at 37ºC, but the reported effect is variable and at times only a 3-fold reduction was observed (Croyle et al., 2004; DePolo et al., 2000) . Murine complement has also been shown to inactivate such vectors (Croyle et al., 2004; Pan et al., 2007) , in one study to the same extent as human complement, and yet this inactivation was insufficient to prevent the transduction observed in the aforementioned in vivo biodistribution study. Taking into consideration that typical complement inactivation studies utilize prolonged incubations (>30 minutes) in vitro, and that once bound to cells vector particles are protected from complement inactiva- tion (Pan et al., 2007) , we must realize that the complement system will provide at best a partial barrier which will reduce but not eliminate the likelihood that accidental exposure to the circulatory system would lead to significant transduction. In summary, there is clearly a potential that retroviral vectors used in research laboratories are capable of transducing significant numbers of human cells after accidental exposure. Important factors which will influence the level of transduction that will occur would be the nature of the envelope used to pseudotype the particles, the type of vector (gamma-retroviral vs. lentiviral), the infectious titer of the material exposed to the subject, the duration of the exposure, the particular tissue exposed, and the level of contact with the circulatory system. For surface contact, it might be expected that VSV-G pseudotyped lentiviral vectors would transduce cell numbers only in the hundreds-to-thousands range, while direct inoculation to the circulation could potentially lead to transduction of many more cells.
The Risk that Accidental Transduction Will Lead to Transformation
The transformation of normal cells into a malignant state is a complex process that involves both increased proliferation and the inactivation of the normal cellular controls that protect against proliferative stress. The pathways involved in these events depend upon the original cell type, and early events in the transformative process may influence which other pathways would collaborate to drive a cell to full malignancy. In the context of evaluating risk resulting from accidental transduction, it would be impossible to define one standard of risk which would apply to all cell types transduced and all vectors used in cancer research. Rather, some contrasting examples from the literature can be used to illustrate critical factors that may impact the risk of tumorigenesis after transduction occurs. E Example 1. Leukemia incidence in human gene therapy experiments. In two separate gene therapy trials for treating X-linked Severe Combined Immunodeficiency (SCID-X1), a gammaretroviral vector expressing the human common γ-chain gene was used to transduce bone marrow-derived CD34+ cells, prior to reintroduction into the patients (autologous transplantation of gene-modified cells). Five of the 20 patients treated in this trial subsequently developed leukemia, and four of these tumors were shown to contain the therapeutic vector inserted into the chromosome near the LMO2 (Limb domain Only 2) gene, directly implicating the transcriptional activation of that gene in the tumorigenic process. The LMO2 gene is critical for hematopoietic development and has been identified as a fusion partner in several T-cell Acute Lymphoblastic Leukemia (ALL) translocations. Aside from the subsequent improvements in gene therapy vector design that this result prompted, it is also relevant to determining the risk of accidental exposure to a retroviral vector expressing the LMO2 gene directly. Recently published quantitation of retroviral integration site preferences have shown that the gamma-retroviral vectors used in these trials appear to integrate near the LMO2 gene approximately 34-fold more frequently than predicted by its size relative to the whole genome (Cattoglio et al., 2010) . This means that in the trial, infusion of 10-50 million transduced CD34+ cells contained approximately 10-50 thousand cells with the vector near the LMO2 gene, which caused leukemia in 4 out of 20 people. It must be considered, however, that this trial involved transduction of CD34+ cells, which are enriched for progenitors and stem cells, and that the cells were introduced into severely immunocompromised infants, both of which could have a profound effect on the frequency of tumor formation. Additionally, other very similar trials to treat a different immunodeficiency (adenosine-deaminase deficiency, or ADA-SCID) have not shown any incidence of tumor formation (in spite of documented vector insertions near LMO2), suggesting that the risk of leukemia additionally depends upon other, more complex aspects of the host environment (Cappelli et al., 2010) . E Example 2. Transduction of murine hematopoietic cells with oncogene-containing vectors. The influence of the developmental status of the transduced cell on the likelihood of tumorigenesis is illustrated in a set of mouse transplantation experiments utilizing gammaretroviral vectors engineered to express one of three oncogenes (LMO2, TCL1, or ΔTrkA, which is a constitutively active mutant of TrkA) (Newrzela et al., 2008) . In this study, either purified mature T-cells (2x10 7 cells/ mouse) or Sca1+ bone marrow cells (5x10 5 cells/ mouse) were transduced with vectors and transplanted into RAG1deficient mice (an immunocompromised host). Remarkably, only the Sca1+ cells, which are enriched for stem and progenitor cells, were able to form leukemias in mice after transduction with oncogene-containing vectors. When GFP-expressing vectors were transduced into Sca1+ cells, or when mature T-cells were transduced with oncogene vectors, no tumors formed in transplant recipients throughout the follow-up period of 284-518 days (using serial transplantation). The Sca1+ cells transduced with oncogene-expressing vectors generated tumors in 100% of the transplanted mice with a latency dependent upon the gene and ranging from 20-400 days. This result provides strong evidence that the likelihood of tumor formation would critically depend upon the developmental status of the cells transduced with oncogene-containing vectors. Vectors with simple reporter genes, however, are unlikely to significantly lead to tumorigenesis, regardless of the cell type transduced.
E Example 3. Mammary tumors after transduction with potently transforming oncogene. A final example of tumor formation by oncogene vectors is described by www.absa.org Applied Biosafety Vol. 16, No. 4, 2011 Siwko et al. (2008) . This study utilized a lentiviral vector expressing the potently transforming middle T antigen gene from mouse polyoma virus (PyMT), and the vector was directly injected into mammary ducts of immunecompetent mice. The lentiviral vectors were pseudotyped with an avian sarcoma-leukosis virus (ASLV) envelope, which limits infectivity to either avian cells or cells engineered to express the tva envelope receptor, providing enhanced safety for work with this tumorigenic vector. The authors used a transgenic mouse expressing the tva receptor in epithelial cells (K19-tva on a FVBx129 background) and injected 10 3 infectious units of the PyMT gene-expressing lentiviral vector. Control injections with comparably prepared reporter vectors allowed a rough approximation of the extent of transduction (<400 cells/gland, with six glands injected / mouse). Remarkably, this procedure produced palpable tumors in 10 of 13 evaluable mice with a mean latency of 3.3 months. Southern blotting of tumor tissue confirmed clonal insertions of the retroviral vector in all of 6 tumors tested. The interpretation of this result with regard to issues of biosafety is that it shows that a very small dose of a potent oncogene-expressing vector can be tumorigenic, even in an immunocompetent host. For the sake of comparison, the chemical mutagen ethylnitrosourea (ENU) also causes mammary tumors in similar mouse strains at a comparable efficiency when injected intraperitoneally at ~1 mg ENU per mouse (Kohlhepp et al., 2001) . Apparently, oncogene-expressing lentiviral vectors can be as tumorigenic as solutions of ENU used for mouse mutagenesis experiments, if not significantly more so. Consideration of these examples from the literature then implicates several critical factors which will determine the risk of oncogene-containing retroviral vectors to laboratory workers. Most critical among these is the nature of the gene being delivered by the vector, with known oncogenes much more likely to induce tumors than other genes. Each vector should, therefore, be evaluated based upon what is known about the gene or genes contained in it, and the effective risk could be anywhere from relatively harmless at one extreme and more dangerous than potent chemical mutagens at the other. Additional factors are the concentration of the vector and the ability of the vector to transduce cell types susceptible to transformation. Retroviral vectors are prepared at a wide range of concentrations, ranging from 10 5 -10 10 TU/ ml, and so an accidental exposure of a few microliters by needlestick or splash can lead to transduction of either very few or very many cells. Given the enhanced ability of retroviruses to transduce blood cells, exposures to the circulatory system would be expected to result in significantly more transduction than surface exposure. Although lentiviruses have an increased capacity for transduction of stem cells relative to MLV, direct comparison between the two systems with regard to oncogene-containing vector risk has not been described, and other aspects of MLV vector biology, such as their propensity to integrate near growth-promoting genes (Mitchell et al., 2004) , warrant that MLV vectors be treated with similar precaution.
Establishing Prudent and Practical Guidelines for Work with Oncogene-Containing Retroviral Vectors
The summary of the above experimental data and concepts is intended to facilitate determination of the optimal best practice with regard to balancing the potential risk of inadvertent exposure to an oncogenecontaining vector with the need to use these valuable tools in the research laboratory. Even if such an accidental exposure never occurs, with the increased number of researchers using these reagents it is certainly possible that over multiple decades one or more of these researchers will get cancer (from independent or natural causes), and it may become important for the institution to confirm that the work with the tumorigenic vector was not in any way responsible. Additionally, if reasonable precautions can be taken to reduce the risk of inadvertent exposure or beneficial prophylactic treatment options can be in place should an accidental exposure occur, then it is important to discuss and implement these precautions and procedures proactively.
The potential for potently transforming oncogene vectors to induce tumorigenesis at very low doses requires that personnel working with this select type of vector be educated as to this risk. Along with this precaution, special attention should be paid to work with these vectors when they are used at very high titer and with sharp instruments that could cause blood exposure (such as syringes with needles). Although this highest risk category might apply only to a few genes, such as PyMT and cancer-associated chromosomal truncation and fusion genes, the potential for genes with milder transformative properties to increase a worker's risk of cancer over the long-term is difficult to quantitate. As such, an open policy of educating all workers involved regarding what is known and not known about these risks is both fair and prudent.
In the event that an accidental exposure occurs, other measures that might ameliorate the potential harmful effects should be considered. Although the retroviral vectors in question perform only a single cycle of transduction into target cells, it is possible that this process could be attenuated by the use of anti-retroviral therapeutics, provided they are administered immediately following exposure. Careful kinetic analysis of HIV transduction kinetics in vitro has shown that reverse transcription and integration of the proviral genome is a relatively slow process, requiring between 12 and 24 hours post-infection in primary human CD4+ cells (Vatakis et al., 2009) . The speed of transduction is dependent upon the duration of stimulation performed in vitro, as reverse transcription occurred more slowly in www.absa.org Applied Biosafety Vol. 16, No. 4, 2011
less activated cells. Additional experiments showed that addition of the HIV reverse transcriptase inhibitors zidovudine (AZT) and efavirenz (EFV) could nearly completely inhibit productive viral replication (as assessed by p24 synthesis), even when added 12 hours after infection, and at 24 hours post-infection the drug still provided 30% of the maximal inhibition. Integrase inhibitors also showed significant inhibition up to 12 hours after infection (Vatakis et al., 2009) . MLV vector transduction can also be inhibited by AZT (a nucleoside analog), but not HIV-targeted non-nucleoside reverse transcriptase inhibitors (NNRTIs). Lastly, as proteolytic maturation of both MLV and HIV vector particles occurs during or soon after release from the producer cell, protease inhibitors will not have any effect on transduction of a target cell. These results suggest that if an exposure occurred in a laboratory, carefully designed anti-retroviral therapy initiated immediately might reduce the number of cells transduced by the vector. Lastly, an increased institutional awareness of the likelihood of such an accidental exposure, and the possibility that it might lead to harmful consequences, might lead to some pragmatic steps to allow attribution of causality should any laboratory workers develop cancer in the future. If vector transduction is causal in such an event, then the tumors will be marked with the integrated vector. To detect these vector DNA sequences, detailed structural information about the vector (i.e., an accurate DNA sequence and map) will be essential for the design of specific probes. Clear designation of the party responsible for storage of these sequences over the long-term would facilitate a determination of whether a retroviral transduction event was involved in tumorigenesis or not.
In summary, the use of oncogene-containing retroviral vectors presents unique challenges with regard to biosafety of laboratory personnel. Although their replication-defective character eliminates the possibility that a viral infection could spread and infect the population at large, it is probable that at least some of these reagents possess the potential to enhance tumorigenesis after direct exposure. In that regard, they might be considered easily inactivated but very potent carcinogens. Relatively simple precautionary measures should significantly reduce the risk to laboratory personnel working with these reagents.
